L-Methionase: A Therapeutic Enzyme to Treat Malignancies

Abstract EN

Cancer is an increasing cause of mortality and morbidity throughout the world.

L-methionase has potential application against many types of cancers.

L-Methionase is an intracellular enzyme in bacterial species, an extracellular enzyme in fungi, and absent in mammals.

L-Methionase producing bacterial strain(s) can be isolated by 5,5′-dithio-bis-(2-nitrobenzoic acid) as a screening dye.

L-Methionine plays an important role in tumour cells.

These cells become methionine dependent and eventually follow apoptosis due to methionine limitation in cancer cells.

L-Methionine also plays an indispensable role in gene activation and inactivation due to hypermethylation and/or hypomethylation.

Membrane transporters such as GLUT1 and ion channels like Na2+, Ca2+, K+, and Cl− become overexpressed.

Further, the α-subunit of ATP synthase plays a role in cancer cells growth and development by providing them enhanced nutritional requirements.

Currently, selenomethionine is also used as a prodrug in cancer therapy along with enzyme methionase that converts prodrug into active toxic chemical(s) that causes death of cancerous cells/tissue.

More recently, fusion protein (FP) consisting of L-methionase linked to annexin-V has been used in cancer therapy.

The fusion proteins have advantage that they have specificity only for cancer cells and do not harm the normal cells.